Hollak CEM - Search Results

1

Hepatocellular carcinoma in Gaucher disease: an international case series.

Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Regenboog M, et al. Among authors: hollak cem. J Inherit Metab Dis. 2018 Sep;41(5):819-827. doi: 10.1007/s10545-018-0142-y. Epub 2018 Feb 8. J Inherit Metab Dis. 2018. PMID: 29423829 Free PMC article.

2

Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients.

Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E. Zimran A, et al. Blood. 1993 Aug 15;82(4):1107-9. Blood. 1993. PMID: 8353277 Free article.

3

Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Aerts JM, Van Weely S, Boot R, Hollak CE, Tager JM. Aerts JM, et al. J Inherit Metab Dis. 1993;16(2):288-91. doi: 10.1007/BF00710267. J Inherit Metab Dis. 1993. PMID: 8411983 Review. No abstract available.

4

The effect of enzyme therapy in a patient with Gaucher disease type III.

Bosman DK, Hollak CE, Aerts JM, Bakker HD. Bosman DK, et al. J Inherit Metab Dis. 1996;19(5):703-4. doi: 10.1007/BF01799852. J Inherit Metab Dis. 1996. PMID: 8892032 No abstract available.

5

Plasma and metabolic abnormalities in Gaucher's disease.

Aerts JM, Hollak CE. Aerts JM, et al. Baillieres Clin Haematol. 1997 Dec;10(4):691-709. doi: 10.1016/s0950-3536(97)80034-0. Baillieres Clin Haematol. 1997. PMID: 9497858 Review.

6

Oligosaccharide excretion in adult Gaucher disease.

de Jong JG, Aerts JM, van Weely S, Hollak CE, van Pelt J, van Woerkom LM, Liebrand-van Sambeek ML, Wevers RA. de Jong JG, et al. J Inherit Metab Dis. 1998 Feb;21(1):49-59. doi: 10.1023/a:1005311430722. J Inherit Metab Dis. 1998. PMID: 9501269

7

The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.

Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, Pöll R. Maaswinkel-Mooij P, et al. J Inherit Metab Dis. 2000 Feb;23(1):77-82. doi: 10.1023/a:1005655031239. J Inherit Metab Dis. 2000. PMID: 10682310

8

Clinically relevant therapeutic endpoints in type I Gaucher disease.

Hollak CE, Maas M, Aerts JM. Hollak CE, et al. J Inherit Metab Dis. 2001;24 Suppl 2:97-105; discussion 87-8. doi: 10.1023/a:1012492429191. J Inherit Metab Dis. 2001. PMID: 11758685 Review.

9

Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.

Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Maas M, et al. AJR Am J Roentgenol. 2002 Oct;179(4):961-5. doi: 10.2214/ajr.179.4.1790961. AJR Am J Roentgenol. 2002. PMID: 12239046

10

Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease.

Vlieger EJ, Maas M, Akkerman EM, Hollak CE, Den Heeten GJ. Vlieger EJ, et al. J Comput Assist Tomogr. 2002 Sep-Oct;26(5):843-8. doi: 10.1097/00004728-200209000-00031. J Comput Assist Tomogr. 2002. PMID: 12439326

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

315 results

Search Page